Hugh Kearney: Highlighting the Relevance of the Inflammasome in Multiple Sclerosis Pathophysiology
Hugh Kearney, Neurologist at Trinity College Dublin, shared on LinkedIn about a recent article he and his colleagues co-authored, adding:
“I am pleased to be involved in this new study from Eric Downer‘s lab in TCD – this new paper highlights the relevance of the inflammasome in the pathophysiology of MS.
NLRP3 has previously been highlighted to be of relevance to progression in MS and our study supports this.”
Title: Elevated expression of the NLRP3 inflammasome in post-mortem brain white matter and immune cells in multiple sclerosis
Authors: Almudena Otálora-Alcaraz, Melody Cui Sun, Nicole Hofman, Lisa Costelloe, Hugh Kearney, Jack A. Prenderville, Eric J. Downer
Read the Full Article on Multiple Sclerosis and Related Disorders.
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS